VIDEO: ANX007 for geographic atrophy demonstrates visual acuity, photoreceptor benefits
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Eleonora M. Lad, MD, PhD, of Duke University Medical Center discusses findings from the phase 2 ARCHER trial investigating ANX007 for geographic atrophy.
The randomized, double-masked study enrolled 270 participants to receive either sham or ANX007 5 mg (Annexon Biosciences) monthly or every other month. ANX007 is a Fab antibody designed to selectively inhibit C1q to treat neurodegeneration, as Healio previously reported.
“This is a novel neuroprotective agent demonstrating benefits for visual acuity and photoreceptor structure in geographic atrophy,” Lad said. “It preserved visual function, reducing risk of [best corrected visual acuity] 15 letter loss by 73%. It also protected retinal structure of photoreceptors and foveal [retinal pigment epithelium] that were most closely associated with vision, and the drug was generally well tolerated.”
References:
- Jaffe G. Protective effects of ANX007 on central macular ellipsoid zone (EZ) and retinal pigment epithelium (RPE) and association with visual acuity in the phase 2 ARCHER GA study. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
- Pearlman J. Preservation of vision by ANX007: Clinical results and anatomic changes from the phase 2 ARCHER trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts